Online inquiry

IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10343MR)

This product GTTS-WQ10343MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL17A&TNFSF13B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002190.3; NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 10673
UniProt ID Q16552; Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10343MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15164MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA T1h
GTTS-WQ8935MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ4832MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BT-061
GTTS-WQ6524MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ2573MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ9456MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ13382MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PR-1594804
GTTS-WQ11522MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MFGR1877S
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW